Table 1.
Vaccine efficacy base input values and ranges used for sensitivity analyses
| Age group (years) | 50–59 | 60–64 | 65–69 | 70–79 | ≥ 80 |
|---|---|---|---|---|---|
| RZV vaccine efficacy 2 doses [21, 30] | |||||
| HZ (%) (range) | 98.4 (95.0, 100) | 98.4 (95.0, 100) | 98.4 (95.0, 100) | 97.84 (94.1, 100) | 97.84 (94.1, 100) |
| PHN (%) (range) | 98.4 (95.0, 100) | 98.4 (95.0, 100) | 98.4 (95.0, 100) | 97.84 (94.1, 100) | 97.84 (94.1, 100) |
| RZV vaccine efficacy 1 dose [22] | |||||
| HZ (%) (range) | 90.0 (58.9, 98.9) | 90.0 (58.9, 98.9) | 90.0 (58.9, 98.9) | 69.5 (24.9, 89.1) | 69.5 (24.9, 89.1) |
| PHN (%) (range) | 90.0 (58.9, 98.9) | 90.0 (58.9, 98.9) | 90.0 (58.9, 98.9) | 69.5 (24.9, 89.1) | 69.5 (24.9, 89.1) |
| ZVL vaccine efficacy [31, 32] | |||||
| HZ (%) (range) | 69.8 (54.1, 80.6) | 63.89 (56.0, 71.0) | 63.89 (56.0, 71.0) | 40.85 (28.0, 52.0) | 18.25 (0, 48.0) |
| PHN (%) (range) | 69.8 (30.8, 89.6) | 65.69 (25.4, 84.2) | 65.69 (25.4, 84.2) | 73.38 (51.6, 85.8) | 39.51 (0, 73.8) |
Further definitions and calculations can be found in SI. VEHZ and VEPHN are vaccine efficacy estimates against herpes zoster and postherpetic neuralgia at year 0, i.e. immediately after vaccination. These values are not fully aligned with clinical trial data reported in corresponding publications, where VEHZ and VEPHN are averaged over 3 years
HZ herpes zoster, PHN postherpetic neuralgia, RZV adjuvanted recombinant zoster vaccine, VE vaccine efficacy, ZVL zoster vaccine live